[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fDT3vZCdpFdlBI1hZxpFktSoexkAyOf5oz3gEPkyHwd0":8,"$fgQ_l-YvJj3uWS0GRuMLfLCzvQ-b-bfbWp_3kAzlib0U":55,"$fPkyvwib0kq_r1vyS68Zhudclq1LOlwAVtE2QnInl5Mg":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},74933,867271,[],"https://ystcdn.venuertc.com/medical/ystApp/1KNmXQDnP2XagGmzBK1qyfRfTWA6Qk1r.png","李浩齐","缙云县新建镇中心卫生院","全科医疗","住院医师",516,0,"肺鳞癌治疗新选择：信迪利单抗的安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/ebd0cc57-7f5c-4be9-95e5-1b35805b5caf.jpg","\u003Cdiv class=\"synd-guide-material\">\n  \u003Ch1 id=\"material_title\" class=\"synd-guide-title\">肺鳞癌治疗新选择：信迪利单抗的安全用药全指南\u003C/h1>\n  \u003Cdiv class=\"synd-guide-intro\">\n    \u003Cp>\n      说起信迪利单抗，很多人首先联想到它在肿瘤免疫治疗中的地位。作为一种新型人源化单克隆抗体，信迪利单抗已广泛应用于多种肿瘤治疗，包括肺部肿瘤。用这样的创新药物时，了解它的用法、潜在反应和日常注意事项，就是每一位患者和家属都必须认真对待的话题。接下来，就给大家详说信迪利单抗安全用药必须掌握的7个关键细节 📝。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 剂型和成分全解析 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#f7fafc 60%,#e6f0f7 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">01. 剂型和成分全解析 🧪\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗的主要成分是人源化抗PD-1单克隆抗体，通过特异性阻断PD-1与其配体的结合，调动身体自身的免疫细胞对抗异常细胞。\n      \u003C/p>\n      \u003Cp>\n        剂型方面，信迪利单抗仅有注射剂型：每瓶通常含有固定剂量（详见包装说明书），需经专业医疗人员配制后，通过静脉点滴输入。该药不能口服，更不能自行配置，更适合作为医院内使用的静脉给药物。\n      \u003C/p>\n      \u003Cp>\n        正确做法：始终在具备条件的医疗机构，由专业医护人员操作配药和输注流程。切勿擅自带出或自行混合配置药液。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02. 作用机制简明说明 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#f0faf7 60%,#eaf2ee 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">02. 作用机制简明说明 🛡️\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗是一种PD-1抑制剂。它通过结合人体T细胞表面的PD-1蛋白，阻断肿瘤细胞“逃避免疫”这一通道，从而帮助免疫系统准确识别并清除异常细胞。\n      \u003C/p>\n      \u003Cp>\n        用个日常的比喻：就像在球场上，信迪利单抗相当于裁判，阻止违规者直接进球，使防守方有更强的话语权。这一机制使身体的免疫防线被激发，但也伴随着免疫反应增强带来的风险。\n      \u003C/p>\n      \u003Cp>\n        需要注意：作用机制并不能决定使用频率、剂量和疗程，这些务必遵医嘱调整，切勿私自改变使用方式。\n      \u003C/p>\n      \u003Cspan class=\"synd-guide-reference\">\n        [参考：Shen, L. et al. (2020). \"Sintilimab, a PD-1 inhibitor, in Chinese patients with advanced solid tumors.\" Cancer Communications.]\n      \u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03. 用药时间及给药方式 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#f6faff 60%,#f3e9f7 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">03. 用药时间及给药方式 ⏰\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗的用药频率是固定周期的静脉点滴，常见方案是每3周一次（q3w）。每次点滴时间多在30-60分钟之间，且必须保证整个输注过程在医院完成。\n      \u003C/p>\n      \u003Cp>\n        正确做法：严格按照处方周期到院输注，不得随意缩短或延长间隔，也不得擅自增加或减少剂量。老年患者（如本案例中69岁男性患者）无需特殊调整，但若身体状况变化，务必即时与主治医师沟通。\n      \u003C/p>\n      \u003Cp>\n        血液成分监测、肝肾功能检测等多项检查需常规配合，确保疗效和安全。\n      \u003C/p>\n      \u003Cp>\n        用药案例：一位69岁男性患者在用于维持治疗阶段，依照q3w方案规律到院输注，良好配合医护观察，降低了用药风险。\n      \u003C/p>\n      \u003Cspan class=\"synd-guide-reference\">\n        [参考：Yang, Y. et al. (2020). \"Efficacy and safety of sintilimab as immunotherapy in China.\" Journal of Hematology & Oncology.]\n      \u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04. 不良反应识别与应对 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#fefbed 60%,#e9f6e9 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">04. 不良反应识别与应对 🚦\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗的常见不良反应包括疲劳、发热、畏寒、皮疹、肝酶升高、白细胞减少等。约有10%以下的患者会出现免疫相关不良反应，例如免疫性皮炎或内分泌功能扰乱。\n      \u003C/p>\n      \u003Cp>\n        正确做法：每次用药后，注意观察是否有发热、寒战、皮肤异常或不适。如有新出现的不良反应，第一时间告知医护人员。某些反应可能推迟出现，治疗期间和治疗后都不能掉以轻心。\n      \u003C/p>\n      \u003Cp>\n        用药案例：一位老年患者输注期间出现畏寒发热，及时向医护反映后调整了后续用药节奏，未发生进一步严重不良反应。\n      \u003C/p>\n      \u003Cp>\n        出现严重不适（如呼吸困难、持续高热等）需立即就医。\n      \u003C/p>\n      \u003Cspan class=\"synd-guide-reference\">\n        [参考：Zhou, C. et al. (2021). \"Safety profile of PD-1 inhibitors in advanced NSCLC: real world data.\" Lung Cancer.]\n      \u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05. 相互作用与用药禁忌 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#e9f4fc 60%,#dbeeed 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">05. 相互作用与用药禁忌 ⚠️\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗与活疫苗、免疫抑制剂（如大剂量皮质类固醇）同时应用会降低药效或加重不良反应。应告知医生所有正在服用或计划服用的处方药、非处方药及保健品。\n      \u003C/p>\n      \u003Cul class=\"synd-guide-list\">\n        \u003Cli>忌与活疫苗同用\u003C/li>\n        \u003Cli>慎用联合免疫抑制剂\u003C/li>\n        \u003Cli>用药期间如需加用其他药物必须凭医师指导\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        禁忌症方面：对本品或其任何成分过敏者禁用，孕妇及哺乳期女性用药需极为慎重，最好遵照医生建议权衡风险与收益。\n      \u003C/p>\n      \u003Cspan class=\"synd-guide-reference\">\n        [参考：KEGG DRUG: Sintilimab. 京都基因与基因组百科全书, 2023.]\n      \u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06. 特殊人群用药指南 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#f3eaf9 60%,#fafafa 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">06. 特殊人群用药指南 🧓👶\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        老年患者通常无需改变信迪利单抗的标准用药方式，但由于合并疾病及身体反应的个体差异应定期随访。如果肝、肾功能异常，要根据医师建议严密监测生化指标变化。\n      \u003C/p>\n      \u003Cp>\n        儿童和青少年人群目前缺乏足够的研究数据，禁止自行使用。\n      \u003C/p>\n      \u003Cp>\n        女性用药方面，孕妇、备孕及哺乳期间应谨慎，明确需要治疗时应权衡利弊并提供知情同意。\n      \u003C/p>\n      \u003Cp>\n        正确做法：每次用药前主动汇报既往疾病、既往药物史及最近的身体变化，不攀比、不自作主张增加用药频次。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07. 储存要求与用药安全 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#f6f9fa 60%,#e4eaf2 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">07. 储存要求与用药安全 📦\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        信迪利单抗必须在2°C-8°C冷藏，勿置于冷冻室。启封后需在规定时间内用完，剩余药液不得再次使用。药品须避光、密闭保存，由医院药房妥善管理，严禁个人带回家中保存或自行处理。\n      \u003C/p>\n      \u003Cp>\n        超过有效期禁止使用；发现药液浑浊或有异物应弃用。\n      \u003C/p>\n      \u003Cp>\n        过期或剩余药品必须交由医疗机构统一销毁，不可随意丢弃或混入生活垃圾。\n      \u003C/p>\n      \u003Cp>\n        出现运输不当、温度异常或包装破损等情况时，应拒收药品，并联系供方或医院处理。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 总结&提醒 -->\n  \u003Csection class=\"synd-guide-section\" style=\"background:linear-gradient(90deg,#fcf7e9 60%,#ffffff 100%);\">\n    \u003Ch2 class=\"synd-guide-h2\">结语：用药安全，每个细节都重要 ✨\u003C/h2>\n    \u003Cdiv class=\"synd-guide-content\">\n      \u003Cp>\n        总的来说，信迪利单抗的注射使用需要在专业医疗机构完成，严格控制给药周期和剂量，并和医护团队密切配合。妥善监测不良反应，遇到任何异常及时就医，远比自行处理来得安全。储存和残余药品的管理尤其需引起重视。\n      \u003C/p>\n      \u003Cp>\n        最后提醒：信迪利单抗不能与活疫苗等药物同用，特殊人群要个性化评估，确保每一次治疗都更安心有效。如有任何疑虑，请随时向医生或临床药师咨询。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"synd-guide-section synd-guide-reference-part\">\n    \u003Ch2 class=\"synd-guide-h2\">参考文献\u003C/h2>\n    \u003Cul class=\"synd-guide-reference-list\">\n      \u003Cli>\n        Shen, L., et al. (2020). Sintilimab, a PD-1 inhibitor, in Chinese patients with advanced solid tumors. \u003Ci>Cancer Communications\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Yang, Y., et al. (2020). Efficacy and safety of sintilimab as immunotherapy in China. \u003Ci>Journal of Hematology & Oncology\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Zhou, C., et al. (2021). Safety profile of PD-1 inhibitors in advanced NSCLC: real world data. \u003Ci>Lung Cancer\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        KEGG DRUG: Sintilimab. Kyoto Encyclopedia of Genes and Genomes, 2023.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.synd-guide-material {\n  font-family: 'PingFang SC', 'Microsoft YaHei', Arial, sans-serif;\n  color: #23282d;\n  background: #f9fcff;\n  max-width: 800px;\n  margin: 40px auto;\n  border-radius: 20px;\n  box-shadow: 0 4px 24px rgba(84,110,122,0.09), 0 1.5px 6px rgba(20,55,106,0.03);\n  padding: 36px 25px;\n}\n.synd-guide-title {\n  font-size: 2.4em;\n  line-height: 1.2;\n  font-weight: 700;\n  color: #145590;\n  text-shadow: 0 2px 8px #e6ebf1;\n  letter-spacing: 1px;\n  margin-bottom: 15px;\n  text-align: center;\n}\n.synd-guide-intro p {\n  font-size: 1.12em;\n  color: #315477;\n  line-height: 1.8;\n  margin-bottom: 32px;\n  background: #eaf4fb;\n  padding: 20px 24px 14px 24px;\n  border-radius: 12px;\n  box-sizing: border-box;\n}\n.synd-guide-section {\n  margin-bottom: 32px;\n  padding: 24px 21px 16px 21px;\n  border-radius: 15px;\n  box-sizing: border-box;\n  position: relative;\n}\n.synd-guide-h2 {\n  font-size: 1.37em;\n  font-weight: 600;\n  color: #28719c;\n  margin-top: 0;\n  margin-bottom: 18px;\n  letter-spacing: 0.5px;\n  position: relative;\n  z-index: 2;\n  display: flex;\n  align-items: center;\n}\n.synd-guide-h2:before {\n  content: '';\n  display: inline-block;\n  width: 16px;\n  height: 16px;\n  background: #c4e0f5;\n  border-radius: 4px;\n  margin-right: 10px;\n}\n.synd-guide-content {\n  font-size: 1.09em;\n  color: #3d465d;\n  line-height: 2.05;\n}\n.synd-guide-list {\n  margin: 16px 0 16px 12px;\n  padding: 0 0 0 18px;\n  color: #364b68;\n}\n.synd-guide-list li {\n  margin-bottom: 8px;\n  line-height: 1.7;\n}\n.synd-guide-content p {\n  margin: 7px 0 16px 0;\n}\n.synd-guide-reference {\n  display: block;\n  font-size: 0.97em;\n  color: #87a9c3;\n  padding: 7px 0 0 0;\n}\n.synd-guide-reference-part {\n  background: #edf1f9;\n  border-radius: 10px;\n  padding: 15px 14px 6px 20px;\n  margin-bottom: 0;\n}\n.synd-guide-reference-list {\n  font-size: 0.98em;\n  color: #576383;\n  padding-left: 20px;\n  margin-top: 9px;\n}\n.synd-guide-reference-list li {\n  margin-bottom: 7px;\n}\n@media (max-width: 800px) {\n  .synd-guide-material {\n    max-width: 97%;\n    padding: 14px 4% 24px 4%;\n    margin: 14px auto;\n  }\n  .synd-guide-title {\n    font-size: 1.5em;\n  }\n  .synd-guide-section {\n    padding: 18px 8px 13px 8px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"synd-guide-material\">\n  \u003Ch1 id=\"material_title\" class=\"synd-guide-title\">肺鳞癌治疗新选择：信迪利单抗的",538,"2025-12-02 01:39:32","信迪利单抗, 肺鳞癌, 免疫治疗, 用药安全, 不良反应","了解信迪利单抗在肺鳞癌治疗中的应用价值，掌握安全用药要点与注意事项，确保每一次治疗都安心有效。","2026-01-12 16:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]